Holocene Advisors, LP Mereo Biopharma Group PLC Transaction History

Holocene Advisors, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.33 - $1.69 $835,627 - $4.28 Million	-2,532,204 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$1.04 - $1.7 $71,853 - $117,453	69,090 Added 2.8%	2,532,204 $2.84 Million
Q4 2021 Feb 14, 2022	BUY	$1.51 - $2.59 $492,101 - $844,068	325,895 Added 15.25%	2,463,114 $3.94 Million
Q3 2021 Nov 15, 2021	BUY	$2.2 - $3.17 $412,460 - $594,317	187,482 Added 9.62%	2,137,219 $5.17 Million
Q2 2021 Aug 16, 2021	BUY	$2.94 - $4.08 $2.41 Million - $3.34 Million	819,750 Added 72.55%	1,949,737 $6.18 Million
Q1 2021 May 17, 2021	SELL	$2.6 - $4.43 $1.52 Million - $2.59 Million	-584,945 Reduced 34.11%	1,129,987 $3.81 Million
Q4 2020 Feb 16, 2021	BUY	$1.95 - $3.6 $3.34 Million - $6.17 Million	1,714,932 New	1,714,932 $6.14 Million

107M

209K

479K

Ticker MREO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 124,986,000
Market Cap $419M
Description
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the tr...

Get notified when there are updates to the investment portfolio of Holocene Advisors, LP, based on Form 13F filings with the SEC.

Stay updated on Holocene Advisors, LP with notifications on news.